Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial
Anne Sophie Kubasch(Leukemia and Lymphoma Society), Uwe Platzbecker(National Center for Tumor Diseases), Silke Gloaguen, Uta Oelschlaegel(University Hospital Carl Gustav Carus), Jan Krönke(Universitätsmedizin Greifswald), Fatiha Chermat(Groupe Francophone des Myélodysplasies), Martin Puttrich(GWT-TUD (Germany)), Jan Moritz Middeke(Fresenius (Germany)), Lionel Adès(Délégation Paris 7), Katja Jersemann(GWT-TUD (Germany)), Richard F. Schlenk(German Cancer Research Center), Carmen Weigt(GWT-TUD (Germany)), Katharina S. Götze(Ludwig-Maximilians-Universität München), Anna Mies(University Hospital Carl Gustav Carus), Katja Sockel(Innsbruck Medical University), Freya Schulze(University Hospital Carl Gustav Carus), Aristoteles Giagounidis(Marien Hospital Düsseldorf), Pierre Fenaux(Saint Louis University Hospital)
Cited by 17
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k